We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00912405
First Posted: June 3, 2009
Last Update Posted: April 20, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Intersect ENT
  Purpose
This study allows continued access to the Sinexus Intranasal Splint while a marketing application is being prepared. This study will generate additional performance, reimbursement and safety data for the steroid-eluting Sinexus Intranasal Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with chronic sinusitis (CS).

Condition Intervention
Chronic Sinusitis Device: Steroid-Eluting Sinexus Intranasal Splint

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

Resource links provided by NLM:


Further study details as provided by Intersect ENT:

Primary Outcome Measures:
  • Safety as Determined by the Frequency of Serious Adverse Local Tissue Response (SALT) [ Time Frame: 30 days ]
  • Device Placement Success Rate [ Time Frame: At the time of procedure ]
    A proportion where the numerator is the number of successful device placements and denominator is the number of attempted sinuses.


Secondary Outcome Measures:
  • Assessment of Changes From Baseline in Intra-ocular Pressure and Lens Opacities [ Time Frame: Baseline and 30 days ]
    Ocular safety was characterized by assessing the frequency and severity of changes from baseline in intra-ocular pressure and lens opacities. No specific pass/fail criteria we specified.

  • Number of Sinuses With Significant Post-operative Adhesion Formation [ Time Frame: 30 days ]
    Adhesions were graded on a 5 point categorical scale with grades 3 and 4 considered clinically significant. 0=none, 1=small/non-obstructing, 2=obstructing/easily separated, 3=dense/obstructing/difficult to separate, and 4=severe/complete adhesion to lateral nasal wall.


Enrollment: 50
Study Start Date: March 2009
Study Completion Date: December 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sinexus Intranasal Splint
Patient receives a drug-coated intranasal splint
Device: Steroid-Eluting Sinexus Intranasal Splint
Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient has a diagnosis of chronic sinusitis
  • Patient has a clinical indication for and has consented to FESS
  • Patient CT scan confirms CS diagnosis within 6 months of procedure
  • CT sacn confirms presence of disease in ethmoid sinus(es)
  • Planned FESS includes unilateral or bilateral total ethmoidectomy

Exclusion Criteria:

  • Immune deficiency (IGG subclass deficiency or IGA deficiency)
  • Oral-steroid dependent COPD, asthma or other condition
  • Clinical evidence of acute bacterial sinusitis
  • History or diagnosis of glaucoma or ocular hypertension
  • Clinical evidence or suspicion of invasive fungal sinusitis
  • Evidence of disease or condition expected to compromise survival or ability to complete follow-up
  • Known history of allergy or intolerance to corticosteroids
  • History of insulin dependent diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00912405


Locations
United States, California
Central California Ear, Nose Thraot
Fresno, California, United States
Sponsors and Collaborators
Intersect ENT
  More Information

Responsible Party: Intersect ENT
ClinicalTrials.gov Identifier: NCT00912405     History of Changes
Other Study ID Numbers: P500-0209
First Submitted: June 1, 2009
First Posted: June 3, 2009
Results First Submitted: October 23, 2014
Results First Posted: April 20, 2015
Last Update Posted: April 20, 2015
Last Verified: March 2015

Keywords provided by Intersect ENT:
Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)

Additional relevant MeSH terms:
Sinusitis
Chronic Disease
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Disease Attributes
Pathologic Processes